Structural studies on avidinorubicin, a novel anthracycline with platelet aggregation inhibitory activity

  • J Antibiot (Tokyo). 1991 Jun;44(6):635-45. doi: 10.7164/antibiotics.44.635.
M Aoki  1 ,  H Shirai ,  N Nakayama ,  Y Itezono ,  M Mori ,  T Satoh ,  S Ohshima ,  J Watanabe ,  K Yokose ,  H Seto
Affiliations
  • 1. Nippon Roche Research Center, Kanagawa, Japan.
PMID: 2071489 DOI: 10.7164/antibiotics.44.635
Abstract

Avidinorubicin (MW 1,214, C60H86N4O22) was isolated from the cultured broth of strain NR0576 (which was identified as Streptomyces avidinii Stapley et al.) by butyl alcohol extraction, Sephadex LH-20 column chromatography and preparative HPLC. Avidinorubicin inhibited thrombin-induced platelet aggregation with an IC50 being 7.9 microM and was determined to be a novel anthracycline possessing two units of a new aminosugar, avidinosamine, in place of two decilonitrose groups in decilorubicin.

Products